Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study

Autor: Fijnvandraat, K., Coppens, M., Kors, A., Zweegman, S., de Meris, J., Goverde, G.J., Jonkers, M.H., Dors, N., Nijziel, M.R., Nieuwenhuizen, L., Meijer, K., Tamminga, R.Y.J., van der Linden, P.W., Ypma, P.F., Eikenboom, H.C.J., van der Bom, J.G., Smiers, F.J.W., Granzen, B., Hamulyák, K., Brons, P., Laros-van Gorkom, B.A.P., Schols, S.E.M., Leebeek, F.W.G., Cnossen, M.H., Boender, J., Atiq, F., van Kwawegen, C.B., Mauser-Bunschoten, E.P., van Galen, K.P.M., van Kwawegen, Calvin B., Atiq, Ferdows, Endenburg, Dara, Fijnvandraat, Karin, van Galen, Karin P.M., Cnossen, Marjon H., Schols, Saskia E.M., Kruip, Marieke J.H.A., van Heerde, Waander L., de Meris, Joke, van der Bom, Johanna G., Eikenboom, Jeroen, Meijer, Karina, Leebeek, Frank W.G.

Publikováno v: In Journal of Thrombosis and Haemostasis December 2024 22(12):3460-3472

Clinically relevant differences between assays for von Willebrand factor activity

Autor: Boender, J., Eikenboom, J., van der Bom, J.G., Meijer, K., de Meris, J., Fijnvandraat, K., Cnossen, M.H., Laros‐van Gorkom, B.A.P., van Heerde, W.L., Mauser‐Bunschoten, E.P., de Maat, M.P.M., Leebeek, F.W.G. ^*

Publikováno v: In Journal of Thrombosis and Haemostasis December 2018 16(12):2413-2424

CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease

Autor: Sanders, Y.V., van der Bom, J.G., Isaacs, A., Cnossen, M.H., de Maat, M.P.M., Laros-van Gorkom, B.A.P., Fijnvandraat, K., Meijer, K., van Duijn, C.M., Mauser-Bunschoten, E.P., Eikenboom, J., Leebeek, F.W.G. ^*, Coppens, M., Kors, A., de Meris, J., Nijziel, M.R., Tamminga, R.Y.J., Ypma, P.F., Smiers, F.J.W., Granzen, B., Hamulyák, K., Brons, P.

Publikováno v: In Journal of Thrombosis and Haemostasis June 2015 13(6):956-966

Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease

Autor: Atiq, F., Heijdra, J., Snijders, F., Boender, J., Kempers, E., Heerde, W.L. van, Maas, D.P.M.S.M., Krouwel, S., Schoormans, S.C., Meris, J. de, Schols, S.E.M., Galen, K.P.M. van, Bom, J.G. van der, Cnossen, M.H., Meijer, K., Fijnvandraat, K., Eikbenboom, J., Leebeek, F.W.G., WiN study Grp

Publikováno v: Blood Advances, 6(18), 5317-5326. AMER SOC HEMATOLOGY
Blood advances, 6(18), 5317-5326. American Society of Hematology
Blood Advances, 6(18), 5317-5326. ELSEVIER
Blood Advances, 6, 18, pp. 5317-5326
Blood Advances, 6, 5317-5326

Contains fulltext : 282506.pdf (Publisher’s version ) (Open Access) Patients with type 1 and type 2 von Willebrand disease (VWD) can be treated with desmopressin. Although a previous study has shown that the location of the causative VWF gene varia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660a6d123da6bb9d0c9353795f615c47
https://hdl.handle.net/1887/3572055

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.